Bluejay Diagnostics (NASDAQ:BJDX) Director Douglas Clark Wurth Acquires 12,500 Shares

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Director Douglas Clark Wurth purchased 12,500 shares of the company’s stock in a transaction dated Saturday, March 14th. The shares were purchased at an average cost of $2.00 per share, for a total transaction of $25,000.00. Following the transaction, the director directly owned 12,608 shares in the company, valued at approximately $25,216. This represents a 11,574.07% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Bluejay Diagnostics Trading Up 3.0%

Shares of BJDX traded up $0.05 during midday trading on Monday, reaching $1.72. 34,940 shares of the stock were exchanged, compared to its average volume of 155,600. Bluejay Diagnostics, Inc. has a 52 week low of $1.63 and a 52 week high of $16.68. The company’s 50 day moving average is $1.90 and its two-hundred day moving average is $3.24. The company has a market capitalization of $1.77 million, a P/E ratio of -0.15 and a beta of 0.72.

Bluejay Diagnostics (NASDAQ:BJDX) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.95) earnings per share for the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Friday, March 27th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

Institutional Investors Weigh In On Bluejay Diagnostics

A hedge fund recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC purchased a new position in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned approximately 9.15% of Bluejay Diagnostics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 18.47% of the company’s stock.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.